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Abstract 
 
The human proteome includes many proteins that are fully disordered or that contain large 
disordered regions. Although these proteins are closely linked with a wide range of human 
diseases, no clinically-approved drug targets them in their monomeric forms. This situation 
arises, at least in part, from the current lack of understanding of the mechanisms by which 
small molecules can bind disordered proteins. To explore possible solutions to this problem, 
we discuss how an overall decrease in the free energy associated with intermolecular binding 
can originate from different combinations of enthalpic and entropic contributions. We then 
propose a mechanism of binding by which small molecules can affect the conformational 
space of a disordered protein by creating an entropic expansion of the system in which 
additional conformations of the protein are increasingly populated. This mechanism can be 
exploited in strategies to modulate the behaviour of disordered proteins, as even small 
changes in their conformational spaces can drastically affect their properties. 
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Disordered proteins and disease 
Disease-modifying proteins involved in cancer, neurodegeneration, cardiovascular disease, 
and diabetes make up about one-third of those encoded by the human genome (Figure 1a). Of 
these proteins, only about 15% are currently considered ‘druggable’, as they are known or 
predicted to interact with drugs [1]. Essentially all clinically-approved small molecule 
therapeutics target structured domains [2, 3], despite the fact that intrinsically disordered 
proteins or intrinsically disordered regions (see Glossary) of otherwise ordered proteins are 
also commonly involved in disease [4–7] (Figure 1a). These disordered proteins, which lack 
a well-defined stable structure, exist in a dynamic equilibrium of conformationally distinct 
states.  
 
Proteins with more than 40 consecutive disordered residues are reported to make up one-third 
to half of the human proteome [8, 9]. These proteins exhibit widely varying degrees of 
disorder, and this disorder is rather evenly distributed. Our analysis using the s2D method 
(see Glossary) [10] indicates that disordered proteins are approximately 40% of the protein-
coding human genome (Figure 1). This result was obtained by defining disordered proteins as 
those that contain more than 40% of their residues in regions of at least 40 consecutive 
disordered amino acids following similar previous conventions [8, 9]. It is increasingly 
recognized that disorder serves a biological role, as conformational heterogeneity granted by 
disordered regions enables proteins to exert diverse functions in response to stimuli. Unlike 
structured proteins, which are essential for catalysis and transport, disordered proteins appear 
crucial for regulation and signaling, acting as network hubs interacting with a wide range of 
biomolecules, rather than just one [4, 11–17]. 
 
Given the variety of their functions, dysregulation of disordered proteins can give rise to 
disease, including cardiovascular disorders, diabetes, cancer, and neurodegeneration [4, 6, 7]. 
There is, however, an underrepresentation of disordered proteins encoded by the so-called 
‘druggable genome’ (Figure 1c), which is the set of all proteins reported or predicted to bind 
small molecules [1–3]. Even in cases in which proteins with disordered regions are targeted, 
most drugs directly target structured domains of these proteins. Overall, despite their high 
prevalence in disease, disordered proteins are not targeted by clinically-available drugs. Here 
we discuss possible strategies to modify this situation to identify opportunities to exploit this 
untapped potential. 
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Small molecules binding to disordered proteins 
 
Major advances have been recently made in understanding the molecular roles disordered 
proteins play in disease [6, 7, 18]. However, the development of therapeutics that target 
disordered proteins is still in its infancy, in part because the highly dynamic nature of these 
proteins renders them difficult to study experimentally. For example, in the case of 
Alzheimer’s disease, despite the enormous efforts over the past two decades to develop drugs 
capable of inhibiting the aggregation process of the disordered amyloid β peptide, currently 
no compound that effectively does so has entered clinical use [18–20]. A recently proposed 
approach to obtain drugs targeting disordered regions relies on the computational docking of 
small-molecule fragments against an ensemble of representative conformations of the protein 
of interest [21]. Its application to α-synuclein, a disordered protein involved in Parkinson’s 
disease, identified a compound that inhibits the aggregation of α-synuclein [21]. However, it 
is still poorly understood whether this compound binds directly to the monomeric protein 
rather than to its aggregated species. A clearer example of direct targeting of monomeric 
disordered proteins is the oncoprotein c-Myc [22–24]. High-throughput screening yielded a 
series of compounds interacting with its disordered regions, which prevent binding to its 
partner, Max. The mechanism of these drug-binding interactions, however, remains unclear 
and these compounds have not yet entered clinical use [22–24, 25].  
 
Disordered proteins populate ensembles of many conformations, each with its own 
occupation probability. The behaviour of disordered proteins is governed by these ensembles 
and can thus be drastically different from that of any individual conformation. Upon 
interacting with other molecules such as protein-binding partners, disordered proteins may 
pay an entropic cost because they restrict their conformation space in the bound form, which 
can be compensated by an enthalpic gain [11, 26]. Conversely, in an alternative scenario a 
change in the behaviour of disordered proteins may be achieved through the use of small 
molecules, such that the conformational space of a disordered protein is not restricted, but 
rather, entropically expanded (see Glossary) by new, transiently bound states with varying 
probabilities. In the following we discuss potential mechanisms through which small 
molecules could be effective at targeting monomeric disordered proteins. 
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Thermodynamics of protein-ligand binding 
 
The binding of two molecules occurs spontaneously when it is associated with an overall 
decrease in free energy (∆𝐺 < 0), where ∆𝐺 indicates the difference between the free energy 
𝐺 of the final state and that of the initial state. This difference can be expressed as the sum of 
enthalpic and entropic contributions  
 
∆𝐺 = ∆𝐻 − 𝑇∆𝑆                                                                                                                            (1) 
 
where the change in enthalpy (∆𝐻) is determined by a variety of interatomic forces, including 
electrostatic, van der Waals and hydrogen bonding interactions, and the entropic contribution 
(∆𝑆) represents the change in the size of the conformational space available to the overall 
system, including the protein, ligand, and solvent molecules. 
 
Enthalpic and entropic factors can either contribute favorably or unfavorably to ∆𝐺, resulting 
in the four possible modes: 1) ∆𝐻 > 0, ∆𝑆 < 0,  2) ∆𝐻 < 0, ∆𝑆 < 0, 3) ∆𝐻 < 0, ∆𝑆 > 0, 
and 4) ∆𝐻 > 0, ∆𝑆 > 0. Only modes 2-4 yield negative ∆𝐺 values, thus leading to binding. 
Protein-ligand binding systems can be characterized experimentally into one of these four 
modes using, for example, isothermal titration calorimetry (ITC) [27]. ITC experiments allow 
direct, in-solution, label-free determination of both ∆𝐺 and ∆𝐻 for a protein-ligand binding 
system, including contributions from the solvent. The difference of these observed values can 
be used to calculate −𝑇∆𝑆 using Eq. 1 [27-29]. While many protein-ligand binding events are 
driven by enthalpic factors, in some cases entropy can contribute favorably towards a negative 
change in free energy, and thus result in binding. 
 
To better understand the role of entropy in protein-ligand binding interactions, we reviewed 
all entries in the Binding Database (BindingDB) for which there are ITC data (139 unique, 
non-mutant entries). We categorized these entries according to the magnitude of the entropic 
contributions [28, 30-33] (Figure 2a). Some enthalpically-favorable interactions come at an 
entropic cost (black points). This compromise is referred to as enthalpy-entropy 
compensation. 
  
In rational drug design, it is possible to optimize the enthalpy to promote binding to a target, 
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and occasionally the entropy is also optimized. This emphasis is reflected by the distribution 
of the entropic contributions to binding across the BindingDB (Figure 2b). We note that 
strong entropic contributions to protein-ligand binding are highly underrepresented in the 
BindingDB. Furthermore, the vast majority of the entropically-favourable interactions in 
Figure 2 are of hydrophobic nature, as binding originates from a large positive solvation 
entropy [27]. Before interacting, protein and ligand are solvated separately. Upon binding, 
which in this context usually involves the burial of hydrophobic surfaces, many water 
molecules from the separate hydration shells surrounding the protein and ligand are freed into 
bulk solvent. This increases the number of conformational states of the water molecules, and 
thus, of the system as a whole, overcoming the loss of entropy due to restraining the molecule 
and binding site [27, 28]. 
 
Interestingly, however, cases have been reported (highlighted as squares in Figure 2a) of 
entropy-driven binding where solvation effects may not fully explain the increase in entropy 
upon binding.  The first of these cases is the binding of a Ca2+ ion to phospholipase D βC2, or 
to phospholipase D αC2 [34]. The second is the binding of a Zn2+ ion to conantokin-G or to 
conantokin-T [35]. These changes in entropy seem to be arising from conformational changes 
in the proteins themselves, rather than from released solvent molecules. More specifically, the 
binding of metal ions may expose hydrophobic groups to water, causing the backbones to 
behave in a disordered manner [34, 35]. The increased conformational flexibility enables the 
protein target to occupy more states, thereby increasing the entropy of the system (Figure 2c).  
 
Such induced disorder-upon-binding mechanisms have been proposed and validated for other 
classes of proteins. For example, one ligand, PD173955, has been optimised to promote 
disorder of the Bcr-Abl kinase activation loop and therefore increases overall binding affinity 
as compared to its parent compound, imatinib [36]. Along similar lines, variable differences 
in the conformational entropy between free and bound states of galectin-3 have been observed 
upon binding to different carbohydrate differences. The extent of this induced conformational 
entropy has been shown to control the affinity [37]. These studies, among others, [38-41] 
support the validity of ligand binding through entropic expansion for disordered proteins. 
 
In contrast to traditional binding scenarios in which a drug locks a protein in an inactive state, 
the entropy-driven binding scenario may appear unconventional due to the multiplicity of low 
populated conformations in which the protein is weakly interacting with the ligand (Figure 
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2c). This mechanism of interaction suggests a more general definition of ‘binding’ than one in 
which two molecules form a stable association through strong intermolecular interactions. 
Within this framework any interaction in which a ligand significantly affects the 
conformational space of a protein may be considered binding. This view raises two issues (see 
Outstanding Questions Box): firstly, by this definition, solutes affecting protein hydration, 
high salt concentrations, and crowding agents that affect the conformational space of a 
disordered protein are be considered as ‘ligands’ even though they are not traditionally 
considered as such. Although discussing binding in this way may be unconventional, we are 
forced here to consider it because it is the natural consequence of entropic expansion.   
 
A second concern is how these interactions can be specific, as binding interactions governed 
by a network of weaker interactions to induce favourable entropic changes may not be 
localized to a single binding region. We propose, however, that a combination of entropically 
and enthalpically favourable interactions can be used to optimize, specific interactions that 
can alter the behaviour of disordered regions. In other words, one way in which ligands may 
bind disordered regions consists of using relatively weak enthalpic interactions to ensure 
specificity, but relying on entropic factors for increasing the binding free energy. Mutagenesis 
studies have confirmed that drugs found to bind to the disordered region of c-Myc have 
specific binding regions 11-29 residues long within the 84-residue long disordered bHLHZip 
domain [42], thus suggesting that specificity may be achievable when binding to disordered 
regions. However, it is possible that these small molecules may bind to other proteins as some 
of their constituent scaffolds have been shown to bind a large number of targets with weak or 
moderate affinity [43].  
 
 
Using entropy to target disordered proteins 
 
Enthalpy-focused rational drug design, which is widely used for targeting globular proteins 
[27], has not yet led to major advances for disordered proteins. While focusing on favourable 
enthalpic contributions may be a good strategy for targeting structured proteins, we suggest 
that exploiting entropically-favourable binding may provide novel opportunities for obtaining 
drugs to target monomeric disordered proteins. We anticipate that many drugs targeting 
disordered proteins will populate the bottom quadrants of Figure 2c by similar mechanisms to 
those described above for metal-binding proteins. Much like phospholipase D and 
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conantokins, the conformational space available to a polypeptide chain may be susceptible to 
entropic expansion upon the introduction of a ligand, thus resulting in an increase the number 
of states accessible to the disordered polypeptide chain itself (Figure 3). Such an increase of 
entropy may result in favorable protein-ligand interactions, and be modulated by hydrophobic 
effects, electrostatics, π-effects, and van der Waals forces.  
 
This type of entropically-favourable binding may be more effective than targeting disordered 
proteins with strong enthalpic or solvent-mediated entropic interactions that stabilize a single 
conformation. Such types of interactions indeed occur for disordered proteins, such as the 
many disorder-to-order transitions reported in the literature [9, 12, 44]. These interactions, 
however, tend to involve large interfaces, which currently can be disrupted by binding the 
structured partner to block the binding region of the disordered protein [11]. We propose that 
small molecules can also be developed to directly target monomeric disordered proteins in 
order to alter their behaviour via entropic expansion. We illustrate this concept in Figure 3, 
which represents the limited conformational space of an unbound disordered protein being 
expanded upon the introduction of a drug. The mechanisms by which this type of binding can 
happen include the disruption or creation of contacts yielding more extended conformations 
or more structured ones, expanding the conformational space of the bound protein with a 
corresponding overall increase in entropy. As new states of the protein are introduced upon 
the addition of a drug, the statistical weights of existing states in the unbound ensemble may 
decrease, thus providing a potential avenue to significantly alter the behaviour of the 
disordered target. 
 
This concept may be used to rationalize simulations performed recently on a peptide fragment 
of c-Myc and its binding partner, the small molecule 10058-F4. The c-Myc peptide was 
observed to occupy an increasingly large number of low populated states upon binding 
10058-F4 as compared to the unbound form [45]. We interpret this observation as an example 
of the extended conformational space of a bound disordered protein and thereby a potential 
increase in the overall entropy of the system. Similar analyses on another c-Myc peptide and 
its binding partner 10074-A4 further suggest that drug binding to c-Myc occurs weakly at 
many binding sites along the binding region [46]. These reports are consistent with the 
hypothesis of an entropy-increasing mechanism, as described above. Further studies will be 
necessary to confirm these conclusions. 
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Additionally, a second relevant example is the MDM2 protein, which contains a large 
disordered lid region. Upon binding some classes of p53/MDM2 antagonists, the base of the 
lid region becomes ordered via contacts with the ligand with an accompanying increase in 
flexibility of the remainder of the disordered region as compared to the disordered state 
[47,48]. In the current attempts to curtail the toxic behavior of disordered proteins, likely 
milestones may include the fine-tuning of flexible disordered regions such as the flexible lid 
of MDM2. 
 
Therapeutic potentials of the entropic expansion mechanism of binding 
Conformational ensembles of disordered proteins are extremely sensitive to external factors. 
Post-translational modifications [49], point mutations [50], and pH changes [51] can 
significantly reweight the states within an ensemble, including introducing nontrivial states 
and significantly decreasing the weights of existing ones. Small changes within ensembles 
can have profound physiological effects. In the case of mutational variants of α-synuclein, it 
was reported that relatively small differences in the ensembles, and more specifically in the 
populations of β-strands [50] and polyproline II [52] secondary structure elements, 
correspond to large differences in the aggregation rates, thus affecting the formation of 
neurotoxic species. 
 
Small molecules can have a similar potential to change the ensembles of disordered proteins 
from one that is disease-promoting to one that may be disease-preventing, thereby enabling 
them to have a therapeutic effect. Earlier in this article, we described drug development 
opportunities aimed at entropically expanding the ensemble, although reweighting, restricting, 
or shifting the ensemble are also candidate strategies to change the behaviour of disordered 
proteins and eliminate disease-promoting conformations.  
 
As is the case of c-Myc described earlier, drugs that target disordered regions have shown 
promising initial results both in vitro and in vivo, and currently more metabolically-stable 
analogs are in development [6, 23, 53]. An ability to modify the behaviour of disordered 
proteins via the use of small molecules may have profound implications for disease. For 
instance, the major neurotoxic agents responsible in Alzheimer’s disease are soluble 
oligomeric species formed by the aggregation of the amyloid β peptide [20, 54, 55]. We thus 
believe that particularly effective therapeutic agents against aggregation may inhibit the 
formation of oligomeric assemblies via entropic expansion of monomeric disordered peptides. 
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Because many of the toxic oligomeric species involved in neurodegeneration are largely 
comprised of disordered proteins, reweighting the monomeric ensembles of these disordered 
proteins may slow down the formation of toxic oligomeric species. As new states are 
introduced, the populations of existing, potentially disease-promoting states will decrease, and 
such an expansion of the ensemble can be achieved by the introduction of certain small 
molecules that increase the entropy of the overall system.  
 
 
Concluding remarks 
 
In most cases the binding of ligands to structured proteins is either driven by enthalpic factors 
or by solvent-mediated entropic interactions such as hydrophobic attraction. In the case of 
disordered proteins, however, we expect that favourable entropic contributions arising from 
the proteins themselves rather than from the solvent may represent an alternative drug-
discovery strategy, which can be then further tunable using enthalpic contributions. 
Disordered proteins have been considered as ‘untargetable’ so far because they do not readily 
lend themselves to enthalpy-driven binding, as no tight binding small-molecules have been 
identified to interact with them (see Outstanding Questions Box). They may be, however, 
more amenable to binding via entropic expansion, which may only require weak enthalpic 
interactions between proteins and ligands. We anticipate that by exploiting recent 
developments in experimental measurements and molecular dynamics simulations it will 
become possible to obtain increasingly accurate estimates of entropic contributions of 
disordered protein-ligand systems, which will hopefully facilitate the rational development of 
small molecules targeting disordered proteins.  
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Glossary 
 
BindingDB (Binding Database).  An online database of measured binding affinities 
(http://www.bindingdb.org). Entries are mainly protein considered to be drug-targets with 
small drug-like molecules. 
 
Disordered proteins or disordered regions. Proteins or protein regions that under native 
conditions do not populate a well-defined conformation, but rather a heterogeneous ensemble 
of states. 
 
Entropic expansion. An increase of entropy of a disordered protein upon the introduction of 
a ligand, whereby the increase arises because the disordered protein populates even more 
states than it did in the unbound form. 
 
Isothermal titration calorimetry (ITC). An experimental technique that can be used to 
determine thermodynamic parameters from a binding interaction. 
 
s2D method.  A computational method to simultaneously predict disordered regions and 
secondary-structure populations of proteins from their amino acid sequences. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  11 
References 
 
1.  Griffith M, et al. (2013) DGIdb: mining the druggable genome. Nat Methods 
10(12):1209–10.  
2.  Russ AP, Lampel S (2005) The druggable genome: An update. Drug Discov Today 
10:1607–1610. 
3.  Hopkins AL, Groom CR (2002) The druggable genome. Nat Rev Drug Discov 1:727–
730. 
4.  Babu MM, van der Lee R, de Groot NS, Gsponer J (2011) Intrinsically disordered 
proteins: Regulation and disease. Curr Opin Struct Biol 21:432–440. 
5.  Tompa P (2012) Intrinsically disordered proteins: A 10-year recap. Trends Biochem Sci 
37:509–516. 
6.  Metallo SJ (2010) Intrinsically disordered proteins are potential drug targets. Curr 
Opin Chem Biol 14:481–488. 
7.  Uversky VN, Oldfield CJ, Dunker AK (2008) Intrinsically disordered proteins in 
human diseases: introducing the D2 concept. Annu Rev Biophys 37:215–246. 
8.  Dunker AK, Obradovic Z, Romero P, Garner EC, Brown CJ (2000) Intrinsic protein 
disorder in complete genomes. Genome Inform Ser Workshop Genome Inform 11:161–
171. 
9.  Dunker AK, Brown CJ, Lawson JD, Iakoucheva LM, Obradović Z (2002) Intrinsic 
disorder and protein function. Biochemistry 41:6573–6582. 
10.  Sormanni P, Camilloni C, Fariselli P, Vendruscolo M (2015) The s2D Method: 
Simultaneous Sequence-Based Prediction of the Statistical Populations of Ordered and 
Disordered Regions in Proteins. J Mol Biol 427(4):982–996.  
11.  Flock T, Weatheritt RJ, Latysheva NS, Babu MM (2014) Controlling entropy to tune 
the functions of intrinsically disordered regions. Curr Opin Struct Biol 26:62–72. 
  12 
12.  Dyson HJ, Wright PE (2005) Intrinsically unstructured proteins and their functions. 
Nat Rev Mol Cell Biol 6:197–208. 
13.  Tompa P, Han K (2012) Intrinsically disordered proteins. Phys Today 65:64.  
14.  Wright PE, Dyson HJ (1999) Intrinsically unstructured proteins: re-assessing the 
protein structure-function paradigm. J Mol Biol 293:321–331. 
15.  Uversky VN (2011) Intrinsically disordered proteins from A to Z. Int J Biochem Cell 
Biol 43:1090–1103. 
16.  Habchi J, Tompa P, Longhi S, Uversky VN (2014) Introducing protein intrinsic 
disorder. Chem Rev 114(13):6561–6588. 
17.  Tompa P (2012) Intrinsically disordered proteins: A 10-year recap. Trends Biochem Sci 
37:509–516.  
18.  Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease: progress 
and problems on the road to therapeutics. Science 297:353–356. 
19.  Rafii MS, Aisen PS (2009) Recent developments in Alzheimer’s disease therapeutics. 
BMC Med 7:7. 
20.  Cohen SI a, et al. (2013) Proliferation of amyloid-β42 aggregates occurs through a 
secondary nucleation mechanism. Proc Natl Acad Sci U S A 110:9758–63.  
21.  Tóth G, et al. (2014) Targeting the intrinsically disordered structural ensemble of α-
synuclein by small molecules as a potential therapeutic strategy for Parkinson’s 
disease. PLoS One 9(2):e87133.  
22.  Hammoudeh DI, Follis AV, Prochownik E V., Metallo SJ (2009) Multiple independent 
binding sites for small-molecule inhibitors on the oncoprotein c-Myc. J Am Chem Soc 
131:7390–7401. 
23.  Follis AV, Hammoudeh DI, Daab AT, Metallo SJ (2009) Small-molecule perturbation 
of competing interactions between c-Myc and Max. Bioorganic Med Chem Lett 
19:807–810. 
24.  Berg T (2010) Small-molecule modulators of c-Myc/Max and Max/Max interactions. 
Curr Top Microbiol Immunol 348:139–149. 
  13 
25.     Cuchillo R, Michel J (2012) Mechanisms of small-molecule binding to intrinsically 
disordered proteins. Biochem Soc Trans 40(5):1004–8. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/22988855. 
26.  Marlow MS, Dogan J, Frederick KK, Valentine KG, Wand AJ (2010) The role of 
conformational entropy in molecular recognition by calmodulin. Nat Chem Biol 6:352–
358. 
27.  Bronowska A (2011) Thermodynamics of Ligand-Protein Interactions: Implications for 
Molecular Design. Thermodyn - Interact Stud - Solids, Liq Gases:1–49.  
28.  Klebe G (2015) Applying thermodynamic profiling in lead finding and optimization. 
Nat Rev Drug Discov 14(2):95–110. 
29.  Chodera JD, Mobley DL (2013) Entropy-enthalpy compensation: role and 
ramifications in biomolecular ligand recognition and design. Annu Rev Biophys 
42:121–42.  
30.  Liu T, Lin Y, Wen X, Jorissen RN, Gilson MK (2007) BindingDB: A web-accessible 
database of experimentally determined protein-ligand binding affinities. Nucleic Acids 
Res 35. 
31.  Chen X, Lin Y, Gilson MK (2001) The binding database: Overview and user’s guide. 
Biopolymers 61:127–141. 
32.  Chen X, Lin Y, Liu M, Gilson MK (2002) The Binding Database: data management 
and interface design. Bioinformatics 18:130–139. 
33.  Chen X, Liu M, Gilson MK (2001) BindingDB: a web-accessible molecular 
recognition database. Comb Chem High Throughput Screen 4:719–725. 
34.  Zheng L, Krishnamoorthi R, Zolkiewski M, Wang X (2000) Distinct Ca2+ binding 
properties of novel C2 domains of plant phospholipase Dα and β. J Biol Chem 
275:19700–19706. 
35.  Prorok M, Castellino FJ (1998) Thermodynamics of binding of calcium, magnesium, 
and zinc to the N- methyl-D-aspartate receptor ion channel peptidic inhibitors, 
conantokin-G and conantokin-T. J Biol Chem 273:19573–19578. 
  14 
36       Crespo A, Fernández A (2008) Induced disorder in protein-ligand complexes as a 
drug-design strategy. Mol Pharm 5(3):430–437.  
37.      Diehl C, et al. (2010) Protein flexibility and conformational entropy in ligand design 
targeting the carbohydrate recognition domain of galectin-3. J Am Chem Soc 
132(41):14577–14589.  
38.  Frederick KK, Marlow MS, Valentine KG, Wand AJ (2007) Conformational entropy in 
molecular recognition by proteins. Nature 448(7151):325–329. 
39.  Chang C-EA, McLaughlin WA, Baron R, Wang W, McCammon JA (2008) Entropic 
contributions and the influence of the hydrophobic environment in promiscuous 
protein-protein association. Proc Natl Acad Sci U S A 105(21):7456–7461. 
40.  Baron R, McCammon JA (2008) (Thermo)dynamic role of receptor flexibility, entropy, 
and motional correlation in protein-ligand binding. ChemPhysChem 9(7):983–988. 
41.  Tzeng S-R, Kalodimos CG (2009) Dynamic activation of an allosteric regulatory 
protein. Nature 462(7271):368–372.  
42.  Follis AV, Hammoudeh DI, Wang H, Prochownik E V., Metallo SJ (2008) Structural 
Rationale for the Coupled Binding and Unfolding of the c-Myc Oncoprotein by Small 
Molecules. Chem Biol 15(11):1149–1155. 
43.     Mendgen T, Steuer C, Klein CD (2012) Privileged scaffolds or promiscuous binders: A 
comparative study on rhodanines and related heterocycles in medicinal chemistry. J 
Med Chem 55(2):743–753. 
44.  Wright PE, Dyson HJ (2009) Linking folding and binding. Curr Opin Struct Biol 
19:31–38. 
45.  Michel J, Cuchillo R (2012) The impact of small molecule binding on the energy 
landscape of the intrinsically disordered protein C-Myc. PLoS One 7. 
46.  Jin F, Yu C, Lai L, Liu Z (2013) Ligand Clouds around Protein Clouds: A Scenario of 
Ligand Binding with Intrinsically Disordered Proteins. PLoS Comput Biol 9. 
47.      Michelsen K, et al. (2012) Ordering of the N-terminus of human MDM2 by small 
molecule inhibitors. J Am Chem Soc 134(41):17059–17067. 
  15 
48.      Bueren-Calabuig J a., Michel J (2015) Elucidation of Ligand-Dependent Modulation of 
Disorder-Order Transitions in the Oncoprotein MDM2. PLOS Comput Biol 
11(6):e1004282. Available at: http://dx.plos.org/10.1371/journal.pcbi.1004282. 
49.  Xiang S, et al. (2013) Phosphorylation drives a dynamic switch in serine/arginine-rich 
proteins. Structure 21:2162–2174. 
50.  Camilloni C, Vendruscolo M (2013) A relationship between the aggregation rates of α-
synuclein variants and the β-sheet populations in their monomeric forms. J Phys Chem 
B 117:10737–10741. 
51.  Hong W, et al. (2005) Periplasmic protein HdeA exhibits chaperone-like activity 
exclusively within stomach pH range by transforming into disordered conformation. J 
Biol Chem 280:27029–27034. 
52.  Porcari R, et al. (2015) The H50Q Mutation Induces a 10-fold Decrease in the 
Solubility of α-Synuclein. J Biol Chem 290(4):2395–2404.  
53.  Jeong K-C, Ahn K-O, Yang C-H (2010) Small-molecule inhibitors of c-Myc 
transcriptional factor suppress proliferation and induce apoptosis of promyelocytic 
leukemia cell via cell cycle arrest. Mol Biosyst 6:1503–1509. 
54.  Jarrett JT, Lansbury PT (1993) Seeding “one-dimensional crystallization” of amyloid: 
A pathogenic mechanism in Alzheimer’s disease and scrapie? Cell 73:1055–1058. 
55.  Knowles TPJ (2009) An Analytical Solution to the Kinetics of Breakable Filament 
Assembly. Science (80) 1533:1533–1537.  
56.  Uversky VN, et al. (2009) Unfoldomics of human diseases: linking protein intrinsic 
disorder with diseases. BMC Genomics 10 Suppl 1:S7. 
57.  Andrea Giandanti AD (2014) On the abundance of Intrinsically Disordered Proteins in 
the Human Proteome and its Relation to Diseases: There is no Enrichment. Biophys 
Bioeng Lett 7(2):27–32.  
 
  16 
 
 
 
  
  17 
 
Figure 1.  Prevalence of disorder in some common human diseases. (a) Venn diagram of 
three subsets of the human proteome. Proteins are defined as ‘disordered’ if they contain more 
than 40% of their residues in regions of at least 40 consecutive disordered amino acids, as 
‘druggable’ if they are known or predicted to interact with drugs [1], and as ‘disease-related’ 
or ‘disease-modifying’ (disease*) if they are involved in cancer, diabetes, neurodegeneration 
or cardiovascular diseases (proteins in these groups were determined with a keyword method 
adapted from Refs. [56, 57]). (b) Fraction of proteins encoded by the human genome (right 
axis) binned according to their content of structural disorder (x-axis). Green bins represent 
highly disordered proteins, and orange bins structured ones. The black line is the cumulative 
distribution function (left axis). Cartoons illustrate ensembles of three proteins with varying 
disorder content. (c) Comparison of the amount of protein disorder encoded by the human 
genome, by the druggable genome, and in disease-related proteins. Proteins are binned 
horizontally by disordered content (color-bar). Black boxes represent the fraction of 
disordered proteins as defined in (a). The analysis of disorder was performed using the s2D 
method [10]; an individual residue was considered disordered if its populations of α-helix and 
β-strand were smaller than 0.5. 
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Figure 2.  Entropic contributions to protein-ligand binding in the BindingDB. (a) Entries 
from the BindingDB are plotted according to their enthalpic (ΔH, x-axis) and entropic (-TΔS, 
y-axis) contributions. Data points are representative of all unique, non-mutant entries in the 
BindingDB and are coloured according to their entropic contributions. Squares represent 
entries in which the release of solvent molecules is not considered to be the cause of the 
change in entropy, but rather the many conformations of the backbone itself. These cases 
include: Ca2+ binding to phospholipase D βC2, Ca2+ binding to phospholipase D αC2 [34]  
Zn2+ binding to conantokin-G, and Zn2+ binding to conantokin-T [35]. (b) Distribution of 
entropic contributions to ΔG. (c) Illustration of a possible entropy-driven binding of Zn2+ to 
conantokins, where the free energy decreases in the presence of Zn2+. This entropy may arise 
from the exposure of the backbone to the solvent, thereby introducing new states in the bound 
form.  
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Figure 3.  Entropic expansion of the conformational space  of a disordered protein upon 
binding a small molecule. A small molecule can interfere with the intramolecular 
interactions within a disordered protein, thereby increasing its entropy by changing the 
statistical weights of the conformations that it populates, in some cases by increasing their 
number. The ensemble on the left represents the conformational space of an unbound 
disordered protein, and the one on the right represents the remodelling of this conformational 
space upon binding a drug (shown in red). Different colors represent how various states may 
be affected upon drug binding.  
